Table 3 Step II: hazard ratios (CIs) of treatment outcome for colorectal cancer patients receiving oxaliplatin, after adjusting for covariates

From: Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array

Outcome measure

Polymorphism

Heterozygote vs wild type

Homozygote mutant vs wild type

Carrier analysis

Age

Performance status

Overall P #

Progression-free survival

ATM rs1801516

0.72 (0.43; 1.21)

4.25 (1.45; 12.44)

4.60 (1.58; 3.37)

0.98 (0.96; 1.01)

1.80 (0.71; 4.55)

0.009

   

P =0.008

P =0.005*

   
 

ERCC5 rs1047768

1.71 (0.98; 2.98)

2.85 (1.42; 5.71)

1.92 (1.13; 3.27)

0.98 (0.96; 1.00)

1.62 (0.63; 4.13)

0.012

   

P =0.003

P=0.016**

   
 

GADD45A rs532446

1.58 (0.95; 2.62)

1.14 (0.53; 2.46)

1.44 (1.04; 1.99)

0.98 (0.96; 1.00)

1.56 (0.60; 4.04)

0.216

    

P=0.029**

   

Overall survival

LIG4 rs1805388

—

—

1.83 (1.11; 3.00)

0.98 (0.96; 1.01)

1.42 (0.50; 4.07)

—

    

P=0.017**

   
 

BARD1 rs2070093

1.81 (1.05; 3.12)

1.56 (0.56; 4.38)

1.76 (1.05; 2.95)

0.98 (0.96; 1.01)

1.38 (0.44; 3.50)

0.094

  

P=0.034

 

P=0.031**

   

Toxicity grade ⩾3

ERCC2 rs238406

0.36 (0.12; 1.09)

0.10 (0.02; 0.62)

0.28 (0.10; 0.81)

3.07 (0.39; 24.29)

1.09 (1.02; 1.17)

0.028

  

P=0.070

P=0.013

P=0.018**

 

P =0.008

 
  1. #P overall log rank P-value; carrier analysis: *P wild-type and heterozygotes vs homozygote mutants; **P heterozygotes plus homozygote mutants vs wild-type patients; performance status defined as stated in the Materials and methods section. All P-values in bold are significant according to the threshold set out in the Materials and methods section; other P-values are shown for clarification of confidence intervals only. In the carrier analysis, the most appropriate model (recessive or dominant) was chosen for combined analysis of genotypes, based on the individual HR of each category. Owing to the small number of LIG4 rs1805388 homozygote mutant patients, no log rank P-value could be calculated to compare the 3 genotypes. SNPs with P<0.01 were selected for further analysis.
Back to article page